Compare PAYX & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYX | EW |
|---|---|---|
| Founded | 1979 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8B | 48.9B |
| IPO Year | 1995 | 1999 |
| Metric | PAYX | EW |
|---|---|---|
| Price | $113.55 | $82.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $111.67 | $96.37 |
| AVG Volume (30 Days) | 3.0M | ★ 4.4M |
| Earning Date | 03-25-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.59% | N/A |
| EPS Growth | ★ 6.77 | N/A |
| EPS | ★ 4.89 | 0.66 |
| Revenue | ★ $6,512,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $19.19 | $13.39 |
| Revenue Next Year | $5.50 | $9.81 |
| P/E Ratio | ★ $22.63 | $127.00 |
| Revenue Growth | ★ 16.88 | 11.55 |
| 52 Week Low | $85.45 | $72.30 |
| 52 Week High | $148.11 | $96.29 |
| Indicator | PAYX | EW |
|---|---|---|
| Relative Strength Index (RSI) | 65.55 | 34.59 |
| Support Level | $108.28 | $82.02 |
| Resistance Level | $117.78 | $86.49 |
| Average True Range (ATR) | 2.99 | 2.30 |
| MACD | 0.10 | -1.08 |
| Stochastic Oscillator | 75.11 | 3.75 |
Paychex is a cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including professional employer organization, or PEO, offerings, enabling clients to reduce HR overhead. Paychex primarily targets small and midsize businesses, although its acquisition of Paycor in 2025 signals the firm's aspirations to expand into the midmarket segment, serving firms with more than 100 employees. As of fiscal 2026, Paychex has approximately 800,000 clients and manages payroll for one in 11 workers in the United States.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.